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Abstract—Impaired glucose metabolism (IGM) and type 2 diabetes (DM-2) are associated with high cardiovascular disease
risk. Increases in peripheral and central artery stiffness may represent pathophysiologic pathways through which glucose
tolerance status leads to cardiovascular disease. Peripheral artery stiffness increases with deteriorating glucose tolerance
status, whereas this trend remains unclear for central artery stiffness. Therefore, we investigated the associations
between glucose tolerance status and estimates of central arterial stiffness. We performed a population-based study of
619 individuals (normal glucose metabolism, n261; IGM, n170; and DM-2, n188) and assessed central artery
stiffness by measuring total systemic arterial compliance, aortic pressure augmentation index, and carotid-femoral
transit time. After adjustment for sex, age, heart rate, height, body mass index, and mean arterial pressure, DM-2 was
associated with decreased total systemic arterial compliance, increased aortic augmentation index, and decreased
carotid-femoral transit time. IGM was borderline significantly associated with decreased total systemic arterial
compliance. Respective regression coefficients (95% confidence intervals) for IGM and DM-2 compared with normal
glucose metabolism were 0.05 (0.11 to 0.01) and 0.13 (0.19 to 0.07) mL/mm Hg for total systemic arterial
compliance; 1.1 (0.2 to 2.5) and 1.6 (0.2 to 3.0) percentage points for aortic augmentation index; and 0.85 (5.20
to 3.49) and 4.95 (9.41 to 0.48) ms for carotid-femoral transit time. IGM and DM-2 are associated with increased
central artery stiffness, which is more pronounced in DM-2. Deteriorating glucose tolerance is associated with increased
central and peripheral arterial stiffness, which may partly explain why both DM-2 and IGM are associated with
increased cardiovascular risk. (Hypertension. 2004;43:176-181.)
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Both impaired glucose metabolism (IGM) and type 2diabetes mellitus (DM-2) are associated with a high risk
of cardiovascular disease and mortality.1,2 The mechanisms
through which these pathologies increase the risk of cardio-
vascular disease remain unclear but might involve increased
arterial stiffness,3–6 which leads to increased systolic blood
pressure and left ventricular mass and hampers coronary
filling during diastole.7
Arterial stiffness varies by region and type of artery. It is
likely that increased stiffness of both peripheral and central
arteries is detrimental. We have previously shown that as
compared with individuals with normal glucose metabolism
(NGM), stiffness of peripheral arteries is increased in both
IGM (femoral and brachial arteries) and DM-2 (femoral,
brachial, and carotid arteries). However, it is unknown
whether central artery stiffness is increased in IGM and
DM-2.
In view of these considerations, we investigated, in a
population-based cohort of 619 individuals, the associations
of glucose tolerance status with arterial stiffness, expressed as
total systemic arterial compliance, which reflects the overall
buffering capacity of the arterial system, mainly of the
proximal aorta;8,9 the aortic augmentation index; and the
height-adjusted carotid-femoral transit time, a surrogate for
carotid-femoral pulse wave velocity,9 which reflects the
stiffness of mainly the descending aorta.8,9
Total systemic arterial compliance was estimated by 2
methods, namely, by the time decay of diastolic aortic
pressure and by the ratio of stroke volume to aortic pulse
pressure. Carotid-femoral transit time estimates the average
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aortic distensibility, or bulk modulus K (KPWV2, where
PWV is pulse wave velocity and  is blood viscosity).10 This
method assumes a uniform aorta and gives compliance of
mainly the descending aorta. However, because most com-
pliance resides in the aorta, this estimate is closely related to
total arterial compliance. The aortic augmentation index
depends on timing of the reflected waves and thus, on pulse
wave velocity, as well as on the magnitude and location of
reflection sites,9 and is therefore a less pure estimate of
arterial stiffness.
Methods
Study Population
For the present investigation, we used data from the 2000 Hoorn
Study follow-up examination and the Hoorn Screening Study.
Details have been described elsewhere.3,11,12 The local ethics com-
mittee approved the study, and written, informed consent was
obtained from all participants. The study population consisted of 822
individuals: 290 with NGM, 187 with IGM, and 345 with DM-2.
General Study Procedures
All hemodynamic measurements were obtained by a single observer
unaware of the participant’s clinical or glucose tolerance status.
Total Systemic Arterial Compliance
Total systemic arterial compliance (mL/mm Hg) was determined
according to 2 methods: the exponential-decay method based on the
Windkessel model13,14 and the ratio of stroke volume to aortic pulse
pressure.15 The first method used data obtained by applanation
tonometry (vide infra). The second method used the ratio of stroke
volume to aortic pulse pressure (in mL/mm Hg) to determine total
systemic arterial compliance, for which stroke volume was calcu-
lated as cardiac output divided by heart rate, and aortic pulse
pressure was calculated by use of a calibration method (vide infra).
Blood Pressure and Aortic Augmentation Index
Brachial artery systolic and diastolic blood pressures were assessed
as previously described.3 Aortic pulse pressure was estimated by 2
methods. The first applied a calibration method, which uses disten-
sion waveforms at the brachial and carotid arteries to calibrate the
pulse pressure at the carotid artery,3 and which is subsequently used
as an estimate of aortic pulse pressure.16 The second applies
applanation tonometry, which uses pressure registrations at the radial
artery to calculate the aortic pulse pressure by use of a generalized
transfer function (vide infra).17 (Numerical values of total systemic
arterial compliance differed markedly, depending on the method
used. However, associations with glucose tolerance status were
comparable, regardless of the method used. We chose to report data
obtained with the calibrated aortic pulse pressure because previous
studies have suggested that this may be the most accurate estimate of
aortic pulse pressure.3,16,18,19)
Radial applanation tonometry was used to obtain the aortic
augmentation index and aortic pulse pressure (vide infra) and was
performed with a Millar piezoresistive pressure transducer connected
to an arterial waveform analysis device (Sphygmocor).3 The aortic
augmentation index was calculated as augmented pressure divided
by (tonometrically derived) central pulse pressure. Because the aortic
augmentation index is a ratio of 2 aortic pressure values, the
influence of any systematic errors in the estimation of aortic pulse
pressure by the transfer function will be minimal.
Carotid-Femoral Transit Time
The carotid-femoral transit time (in ms) is the travel time of a
pressure wave from the common carotid to the femoral artery, a
measure of the aortic (thoracic-abdominal) compliance. It is closely
related to carotid-femoral pulse wave velocity,9 ie, length of the
carotid-femoral arterial segment divided by carotid-femoral transit
time. However, because noninvasive measurement of this length
might introduce error, especially in obese and older20 patients, we
chose to use carotid-femoral transit time and to adjust for height in
the statistical analyses. We determined the carotid-femoral transit
time by continuous measurement of the diameter (distension curves)
of the right common carotid artery and the right femoral artery
diameter.3 We then determined the average time delay (mean of 3
recordings of 4 seconds per artery) from the electrocardiograph
trigger to 10% of the ascending slope of the distension curve of both
arteries and subtracted the carotid value from the femoral value to
obtain the carotid-femoral transit time.14 Reproducibilities of the
time-decay method, carotid pulse pressure, augmentation index, and
carotid-femoral transit time have been reported.3,14
Statistical Analyses
All analyses were performed with SPSS 9.0.1 for Windows. We used
multiple linear regression analyses to investigate the associations
between glucose tolerance status and total systemic arterial compli-
ance, aortic augmentation index, and carotid-femoral transit time. All
associations were first analyzed without adjustments and then with
adjustment for potential confounders, such as age, sex, heart rate,
height, body mass index, and brachial mean arterial pressure.
Probability values 0.05 were considered statistically significant.
Results
All analyses presented were performed in 4 groups of patients
with the following glucose tolerance status: NGM, impaired
fasting glucose2 (n89), impaired glucose tolerance2
(n108), and DM-2. These analyses showed no significant
differences between the impaired fasting glucose and im-
paired glucose tolerance groups (data not shown), and there-
fore, we pooled these 2 groups as the IGM group.
Baseline characteristics are shown in Table 1. Of the 822
participants, 18 did not take part in examinations for logistical
reasons; in 8, vascular examinations failed for technical
reasons. In the remaining 796 individuals, qualitatively sat-
isfactory total systemic arterial compliance measurements for
the time-decay method were available for 556 individuals
(owing to device availability) and for the ratio of stroke
volume to aortic pulse pressure for 511 individuals (owing to
technical reasons). The main reason for missing (carotid)
ultrasound data was poor definition of the arterial wall
attributable to obesity (body mass index of those with versus
those without qualitatively satisfactory examinations,
26.93.3 versus 31.35.6 kg/m2). Aortic augmentation in-
dex was available for 619 individuals (owing to device
availability) and carotid-femoral transit time for 319 (again
owing to device availability). Device availability was not
related to the participant’s clinical status.
Total systemic arterial compliance, as determined by the
time-decay method, decreased with deteriorating glucose
metabolism status, but this was not statistically significant
after adjustment, the most important confounder being mean
arterial pressure (Table 2). Total systemic arterial compli-
ance, as determined by the ratio of stroke volume to aortic
pulse pressure, decreased with deteriorating glucose metabo-
lism status (Table 2). Compared with NGM, both IGM and
DM-2 were associated with decreased total systemic arterial
compliance. This decrease was significantly more severe in
DM-2 than in IGM (Table 2 and Figure 1). Total systemic
arterial compliance calculated with aortic pulse pressure, as
measured by tonometry, showed similar results, although
absolute estimates were higher (adjusted estimated means
Schram et al Central Arterial Stiffness and Glucose Metabolism 177
were 1.27, 1.21, and 1.14 mL/mm Hg [P0.001] in the
NGM, IGM, and DM-2 groups, respectively).
The aortic augmentation index increased with deterio-
rating glucose metabolism status. Compared with NGM,
DM-2 was associated with a significantly increased aortic
augmentation index, but IGM was not, although values
were intermediate between those for NGM and DM-2
(Table 2 and Figure 1). Carotid-femoral transit time
decreased with deteriorating glucose metabolism status.
Compared with NGM, DM-2 was associated with a signif-
icantly decreased carotid-femoral transit time, but IGM
was not (Table 2 and Figure 1).
Additional Analyses
Impact of Glucose and Insulin
To estimate the contribution of hyperglycemia and hyperin-
sulinemia to the increase in central arterial stiffness indices
associated with IGM and DM-2, we compared the results of
the aforementioned analyses with those additionally adjusted
for glycosylated hemoglobin (or fasting or postload glucose
levels) and insulin concentrations (or homeostasis model of
assessment). This showed that 15% to 50% of the decrease
in total systemic arterial compliance and10% to 40% of the
increase in aortic augmentation index could be explained by
these estimates of hyperglycemia, whereas hyperinsulinemia
TABLE 1. Baseline Characteristics of the Study Population
NGM (n261) IGM (n170) DM-2 (n188) P for Trend
Age, y 68.66.0 69.76.1 68.08.6 0.06
Sex, M/F, n/n 131/130 83/87 102/86   
Fasting glucose, mmol/L 5.40.4 6.10.5 7.81.9 0.001
Postload glucose, mmol/L 5.61.1 8.01.7 11.62.9 0.001
Glycosylated hemoglobin, % 5.70.4 5.90.4 6.60.9 0.001
Fasting insulin, pmol/L 47 (35–60) 65 (50–87) 80 (56–106) 0.001
Insulin resistance, arbitrary units (HOMA;
n257, 165, 170)*
1.57 (1.16–2.05) 2.53 (1.87–3.19) 3.55 (2.53–5.37) 0.001
Brachial blood pressure, mm Hg
Systolic 13720 14517 14920 0.001
Diastolic 759 789 799 0.001
Mean arterial 9612 10010 10312 0.001
Pulse 6316 6614 7015 0.001
Heart rate, bpm 629 639 6310 0.19
Body mass index, kg/m2 26.23.3 27.83.9 28.73.7 0.001
Waist-to-hip ratio 0.900.09 0.940.08 0.960.09 0.001
Hypertension, %† 38 49 67 0.001
Use of antihypertensive drugs, % 25 34 50 0.001
Total cholesterol, mmol/L 5.81.0 5.81.0 5.61.1 0.10
LDL cholesterol, mmol/L 3.70.9 3.70.9 3.50.9 0.08
HDL cholesterol, mmol/L 1.50.4 1.50.4 1.30.3 0.001
Triglycerides, mmol/L 1.2 (0.9–1.6) 1.3 (1.0–1.8) 1.6 (1.2–2.2) 0.001
Lipid-lowering medication, % 11 17 19 0.05
Current smoking, % 15 18 11 0.17
Microalbuminuria, % 11 14 19 0.05
Serum creatinine, mol/L 9514 9515 9622 0.58
Prior cardiovascular disease, % 41 46 53 0.04
Total systemic arterial compliance (time-decay
method), mL/mm Hg
0.760.32 0.720.29 0.690.30 0.11
Total systemic arterial compliance (SV/aortic
PP), mL/mm Hg
1.130.35 1.040.29 0.930.32 0.001
Aortic augmentation index, % 31.58.9 32.98.5 33.08.7 0.13
Carotid-femoral transit time, ms 5617 5415 5317 0.34
SV indicates stroke volume; pp, pulse pressure, HOMA, homeostasis model of assessment. Other abbreviations are as defined in
text. Data are presented as meanSD or as median (interquartile range).
*Data on HOMA were missing for n9 and could not be calculated for 18 DM-2 subjects because of insulin treatment.
†Hypertension was defined as systolic blood pressure 140 and/or diastolic pressure 90 and/or use of antihypertensive
medication.
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did not contribute (data not shown). The association of
carotid-femoral transit time with DM-2 could not be ex-
plained by hyperglycemia or hyperinsulinemia.
Impact of Additional Adjustments
Additional adjustments of the associations of glucose metab-
olism status with total systemic arterial compliance, aortic
augmentation index, and carotid-femoral transit time for the
presence of hypertension, use of antihypertensives (including
angiotensin-converting enzyme inhibitors), waist-to-hip ratio,
triglycerides, total cholesterol, HDL cholesterol, LDL cho-
lesterol, use of lipid-lowering medication, current smoking,
serum creatinine, microalbuminuria, and prior cardiovascular
disease did not materially change the results (data not shown).
Discussion
The main outcome of this population-based study is that
DM-2 is associated with decreased total systemic arterial
compliance, increased aortic augmentation index, and de-
creased carotid-femoral transit time, independently of age,
sex, mean arterial pressure, heart rate, body mass index, and
other potential confounders. In IGM, values of central artery
stiffness were intermediate between those of the groups with
NGM and DM-2 (Figure 1). Part of these associations could
be explained by short-term hyperglycemia. Taken together
with the data from our previous report on peripheral artery
stiffness,3 these data suggest that central and peripheral
arterial stiffness increase in both IGM and DM-2 and that
these changes are greater at peripheral than at central sites
(Figure 2).
Total systemic arterial compliance was significantly de-
creased in both IGM and DM-2. Total systemic arterial
compliance is an estimate of the buffering capacity of the
entire arterial system and is an important determinant of
myocardial workload. Changes in total systemic arterial
compliance and thus, in properties of the proximal aorta, were
less severe in IGM than in DM-2. As have others,21 we
observed differences in the association of glucose metabolism
with total systemic arterial compliance, as determined by the
time-decay method versus the ratio of stroke volume to aortic
pulse pressure. These differences might be due to the fact that
total systemic arterial compliance as determined by the
time-decay method is computed by combining the results of
different measurements, which results in an increase in
TABLE 2. Total Systemic Arterial Compliance, Aortic Augmentation Index, and Carotid-Femoral Transit
Time According to Glucose Tolerance Status
IGM DM-2
 (95% CI)  (95% CI) P for Trend
Total systemic arterial compliance (time-decay
method), mL/mm Hg
Unadjusted model 0.04 (0.10 to 0.03) 0.06 (0.13 to0.00)* 0.112
Adjusted model 0.01 (0.04 to 0.06) 0.03 (0.08 to 0.02) 0.381
Total systemic arterial compliance (sv/aortic
pp), mL/mm Hg
Unadjusted model 0.09 (0.16 to0.02)* 0.20 (0.25 to0.14)*‡ 0.001
Adjusted model 0.05 (0.11 to 0.01)† 0.13 (0.19 to0.07)*‡ 0.001
Aortic augmentation index, % point
Unadjusted model 1.4 (0.3 to 3.1) 1.5 (0.1 to 3.1)† 0.129
Adjusted model 1.1 (0.2 to 2.5) 1.6 (0.2 to 3.0)* 0.059
Carotid-femoral transit time, ms
Unadjusted model 1.26 (6.04 to 3.53) 3.08 (7.22 to 1.06) 0.314
Adjusted model 0.85 (5.20 to 3.49) 4.95 (9.41 to0.48)*§ 0.079
Results are expressed as regression coefficients () and 95% confidence intervals (95%CI). Adjustments were made for sex, age,
heart rate, body mass index, and mean arterial pressure. Mean arterial pressure was the main confounder of these associations.
NGM indicates normal glucose metabolism; IGM, impaired glucose metabolism; DM, type 2 diabetes mellitus; sv, stroke volume;
pp, pulse pressure.
*P0.05 vs NGM; †0.05P0.10 vs NGM; ‡P0.05 vs IGM; §0.05P0.10 vs IGM.
Figure 1. Adjusted estimated means of total systemic arterial
compliance, carotid-femoral transit time, and aortic augmenta-
tion index according to glucose metabolism status. Values were
adjusted for sex, age, heart rate, height, body mass index, and
mean arterial pressure. *P0.05; sv indicates stroke volume; pp,
pulse pressure.
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measurement error, as expressed by a relatively large stan-
dard deviation of this method.
The aortic augmentation index was increased both in
impaired glucose tolerance and more severely so, in DM-2
(Figure 1). The aortic augmentation index depends not only
on arterial stiffness but also on the number and location of
reflection sites and the amplitude and timing of the reflected
wave. Because we cannot discriminate between these deter-
minants of the augmentation index, this might mean that,
possibly due to the development of atherosclerotic plaques,
reflection sites in IGM are located more centrally than in
NGM and that these changes are more pronounced in DM-2.
Alternatively or additionally, it might mean that increases in
arterial stiffness are responsible for the more pronounced
changes in DM-2.
The use of a generalized transfer function to calculate the
aortic augmentation index has been criticized on methodolog-
ical grounds.22 We acknowledge, therefore that the absolute
values we found may be considered questionable. However,
if the use of a generalized transfer function introduces errors,
then these errors will presumably be similar, regardless of
glucose tolerance status. Therefore, our qualitative conclu-
sion that the aortic augmentation index increases with dete-
riorating glucose tolerance is likely to be valid.
Carotid-femoral transit time was decreased in DM-2 but
not clearly so in IGM. The carotid-femoral transit time
adjusted for height was used as a surrogate for carotid-
femoral pulse wave velocity9; it represents the stiffness of
mainly the descending aorta and is determined predominantly
by the elastic properties of the aortic wall. Because of the
relatively small number of observations in IGM, we could not
establish with certainty whether the carotid-femoral transit
time in this group was normal or decreased, and this issue
requires further study. In addition, we may have underesti-
mated the association between carotid-femoral transit time
and glucose tolerance status for 2 reasons. First, aging is
associated with increases in aortic length, and this is thought
to be more pronounced in DM-2. Second, we measured
carotid-femoral transit time after 15 minutes of supine rest to
reach a steady state with regard to heart rate and blood
pressure. During the examination, heart rate and blood
pressure did not change. Therefore, it is unlikely that changes
in isovolumetric contraction time, for instance, occurred.
However, if such changes did occur, it is reasonable to
assume that they occurred randomly over the study popula-
tion (ie, equally in NGM, IGM, and DM-2). These random
changes (ie, noise) would then weaken the association be-
tween glucose tolerance status and carotid-femoral transit
time.
Compared with changes in peripheral artery stiffness,3 the
changes in central artery stiffness with deteriorating glucose
tolerance status were relatively small. In peripheral arteries,
ie, the brachial, femoral, and carotid, stiffness estimates
decreased by 19% to 31% from NGM to DM-2,3 compared
with a 2% to 11% decrease in estimates of central artery
stiffness (Figure 2).
Our study extends the findings of other studies, which were
relatively small,23,24 concerned selected populations,23–26 or
targeted only 1 estimate of central artery stiffness.23,24,26–28 In
addition, our study is the first to demonstrate an association
between IGM and total systemic arterial compliance and
aortic augmentation index.
These data raise the question of whether the increases in
central and peripheral artery stiffness with deteriorating
glucose tolerance develop in a certain pattern over time.
Wittekoek et al29 have previously suggested that the increase
in arterial stiffness starts at peripheral sites and then extends
to central arteries. In contrast, Kimoto et al28 have suggested
that increases in arterial pulse wave velocity in DM-2
preferentially occur at central arteries, not at peripheral sites.
However, both studies had a cross-sectional setting, whereas
longitudinal studies are necessary to investigate these issues.
We show that in contrast to increases in peripheral artery
stiffness,3 increases in central artery stiffness can, to an
important extent, be explained by relatively short-term hy-
perglycemia. This suggests that hyperglycemia causes impor-
tant quantitative and qualitative changes in arterial wall
elastin and collagen of central arteries. As in peripheral
arteries, another part of these changes may be attributed to
other mechanisms, such as glycation of proteins and the
formation of advanced glycation end products,30 although the
mechanisms by which these changes in arterial stiffness occur
are not fully understood. Advanced glycation end products
can form cross-links in collagen fibers, thereby decreasing the
distensibility of the arterial wall. Further evidence for their
role in arterial stiffness is provided by studies showing that
increases in arterial stiffness are prevented or reduced by
treatment with aminoguanidine,31 which inhibits the forma-
tion of advanced glycation end products, or ALT-711,32
which breaks down cross-links of advanced glycation end
products.
Our study had some limitations. First, our study population
was relatively old. This might have caused an underestima-
tion of the association of arterial stiffness with glucose
metabolism because of selective mortality of individuals with
DM-2 and stiff arteries. Second, our data were cross sec-
tional. Therefore, we could not evaluate whether the changes
in arterial stiffness develop in a certain pattern over time.
Figure 2. Adjusted percentages of change in peripheral arterial
stiffness (local arterial distensibility coefficients [DC] of the bra-
chial, femoral, and carotid artery) and central arterial stiffness
(total systemic arterial compliance, carotid-femoral transit time,
and aortic augmentation index) in DM-2 and IGM compared
with NGM. To facilitate direct comparison of peripheral and cen-
tral stiffness indices, we expressed these data as percentage
change from NGM to IGM and to DM-2. Data were adjusted for
sex, age, heart rate, height, body mass index, and mean arterial
pressure.
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In conclusion, our data show that IGM and DM-2 are
associated with decreased total systemic arterial compliance,
increased aortic augmentation index, and decreased carotid-
femoral transit time, the latter in DM-2 only. These increases
in central artery stiffness are more pronounced in DM-2.
Taken together with our previous report,3 we show that
changes in arterial stiffness are worse at peripheral than at
central arteries in both IGM and DM-2. Deteriorating glucose
tolerance, therefore, is associated with a generalized increase
in arterial stiffness, which provides a framework for under-
standing why both DM-2 and IGM are associated with an
increased risk for stroke, heart failure, and myocardial
infarction.
Perspectives
Our data provide evidence that central artery stiffness is
associated with glucose tolerance status. A crucial next step is
to investigate whether measures of central artery stiffness
have prognostic value in DM-2, as they do in other popula-
tions.33 If so, these measures could be used in clinical practice
for risk assessment and to monitor the effects of interventions
to decrease arterial stiffness. The method to do this should be
reproducible and easy to learn, and the device and software
should be robust and not too expensive. Measurement of both
carotid-femoral pulse wave velocity by use of the Complior
device and aortic augmentation index fulfill these criteria. At
present, most prospective data come from measurement of
pulse wave velocity.33
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